Table 1: Eleven major studies of CSF biomarkers for AD published between 1998 and 2009.

Studyyearsubjectsbiomarkersensitivityspecificityother

Kanai199893 AD, 54 cont, 33 nAD, 56 NDAβ40, Aβ42, Tau71~91%83%Multicenter, prospective

Hulstaert1999150 AD, 100 cont, 79 nAD, 84 NDAβ42, Tau85%86%10 European center

Knopman20013 Class II, III studiesAβ42, Tau80~97%86~95%System review AAN

Andreasen2001163 AD, 23 VaD, 20 MCI, 9 DLB, 8 ND,
18 cont
Aβ42, Tau75~94%89~100%1 Y-prospective

Itoh2001236 AD, 239 nAD/ND, 95 cont,PTau19985%85%multicenter

Shoji2002366 AD, 181 cont,
168 nAD, 316 ND
Tau59%90%multicenter

Clark2003106 dementia, 73 contAβ42, Tau85%84%2~8 Y follow up autopsy confirmed

Sunderland200317Aβ42 studies, 34 tau studies
(3133 AD versus 1481 control)
Aβ42, Tau92%89%Meta-analysis

Blennow200341Tau studies
(2500 AD versus 1400 cont)
15Aβ42 studies
(600 AD versus 450 cont)
11p-Tau studies
(800 AD versus 370 cont)
Aβ42,
Tau,
PTau
Aβ42/tTau
86%
90%
92%
85~94%
90%
81%
80%
83~100%
Systematic review
Early AD, MCI

Hampel2004161 AD/FTD/DLB/VaD, 45 contPTau231
pTau181
pTau199
85%83%,
79%,
60~71%
International harmonization

GTT32004243 AD, 91 cont, 152 nAD, 157 NDAβ40, Aβ42, Tau80%84%Continuous GTT1